IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

Citation:
Attallah, A. M., D. Omran, M. A. Abdelrazek, M. Hassany, S. Saif, R. E. E. Aza Farid3, R. E. Essawey, M. A. Ghaffar, M. Aabdelghany, and A. Yosry, "IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy", Journal of Genetic Engineering and Biotechnology, vol. 19, pp. 150-160, 2021.